Colorectal cancer (CRC) | Flatiron Health

Immune checkpoint inhibitor therapy for metastatic colorectal cancer: real-world practice patterns and predictors of overall survival →

Bari, S, Matejcic, M, Kim, R, Xie, H, Carballido, E, Sahin, I, Powers, B, Felder, S, Schmit, SL

April 2021

AACR Annual Meeting

The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies →

Shaw, JL, Nielson, CM, Park, JK, Marongiu, A, Soff, GA

February 2021

European Journal of Haematology

RAS amplification as a negative predictor of benefit from anti-EGFR containing therapy regimens in metastatic colorectal cancer →

Schrock, AB, Lee, JK, Sandhu, J, Madison, RW, Cho-Phan, C, Snider, JW, Castellanos, EH, Venstrom, JM, Fakih, M

January 2021

The Oncologist

Flatiron-authored

Real-world data (RWD) survival analysis of first line (1L) metastatic colorectal cancer (mCRC) patients (pts) with BRAF V600 and non-V600, KRAS G12 and G13, and NRAS mutations →

Gershon, A, Machado, R, Trinh, H, Julian, C, Shi, Z, Zhang, Q, Yan, Y

September 2020

ESMO Annual Congress

The adoption of immune checkpoint inhibitors and patterns of care at the end of life →

Riaz, F, Gan, G, Li, F, Davidoff, AJ, Adelson, KB, Presley, CJ, Adamson, BJS, Shaw, P, Parikh, RB, Mamtani, R, Gross, CP

May 2020

ASCO Annual Meeting

Flatiron-authored

Real-world outcomes of patients with BRAF-mutated mCRC treated in the United States →

Braithwaite, M, Nevala-Plagemann, C, Baron, K, Halland, B, Garrido-Laguna, I, Pappas, LM, Moser, JC

May 2020

ASCO Annual Meeting

Primary tumor location and survival in colorectal cancer: A retrospective cohort study →

Aggarwal, H, Sheffield, KM, Li, L, Lenis, D, Sorg, RA, Barzi, A, Miksad, RA

April 2020

World Journal of Gastrointestinal Oncology

Flatiron-authored

Assessing real-world biomarker testing rates in metastatic colon cancer →

Nakhoda, S, Deng, M, Iyer, P, Handorf, E, Jain, R, Meropol, NJ, Dotan, E

January 2020

ASCO GI Symposium

Flatiron-authored

Prognostic significance of cancer patient reported outcomes in cancer →

Kerrigan, KC, Patel, SB, Halland, B, Ose, D, Chalmers, AW, Haydell, T, Meropol, NJ, Akerley, WL

January 2020

Journal of Oncology Practice

Flatiron-authored

Validation of diagnosis codes to identify side of colon in an electronic health record registry →

Luhn P, Kuk D, Carrigan G, Nussbaum N, Sorg R, Rohrer R, Tucker MG, Arnieri B, Taylor MD, Meropol NJ

August 2019

BMC Medical Research Methodology

Flatiron-authored

Affordable Care Act Medicaid expansion impact on racial disparities in time to cancer treatment →

Adamson B, Cohen AB, Estevez M, Magee K, Williams E, Gross CP, Meropol NJ, Davidoff AJ

June 2019

ASCO Annual Meeting

Flatiron-authored

Utilization and reach of the Fight Colorectal Cancer Late Stage MSS CRC Clinical Trial Finder →

Garcia R, Dwyer A, Worrall S, Heery CR, Deming DA, Benson AB, Davis A.

June 2019

ASCO Annual Meeting

Machine Learning Model for Cancer Biomarker Identification in Electronic Health Records →

Ambwani G, Cohen A, Estévez M, Singh N, Adamson B, Nussbaum N, Birnbaum B

May 2019

ISPOR Annual Meeting

Flatiron-authored

Primary tumor location (PTL) and survival outcomes in a real world cohort of KRAS wild-type (WT) metastatic colorectal cancer (mCRC) patients →

Aggarwal, H, Sheffield, KM, Li, L, Lenis, D, Sorg, RA, Miksad, RA

March 2019

NCCN Annual Conference

Flatiron-authored

Disease Control With FOLFIRI Plus Ziv-aflibercept (zFOLFIRI) Beyond FOLFIRI Plus Bevacizumab: Case Series in Metastatic Colorectal Cancer (mCRC) →

El-Deiry WS, Winer A, Slifker M, Taylor S, Adamson BJS, Meropol NJ, Ross EA

March 2019

Frontiers in Oncology

Flatiron-authored

Treatment patterns and survival outcomes for patients receiving second-line treatment for metastatic colorectal cancer in the USA →

Hess LM, Cui ZL, Mytelka DS, Han Y, Goodloe R, Schelman W

January 2019

International Journal of Colorectal Disease

Development and Validation of a High-Quality Composite Real-World Mortality Endpoint →

Curtis MD, Griffith S, Tucker M, Taylor M, Capra W, Carrigan G, Holzman B, Torres AZ, You P, Arnieri B, Abernethy AP

June 2018

Academy Health Annual Research Meeting

Flatiron-authored

Risk Stratification Using Patient-Reported Outcomes (PROs) in Patients (pts) with Advanced Cancer →

Patel SB, Haaland B, Ose D, Haydell T, Martineau J, Dunson W, Chalmers AW, Cannon L, Kissell B, Meropol N, Akerley W

June 2018

ASCO Annual Meeting

Flatiron-authored

Age-Related Real-World Outcomes for Patients (pts) with Metastatic Colorectal Cancer (mCRC) →

Curtis MD, Nussbaum N, Hamrick HJ, Bennette CS, Meropol N, Miksad RA

June 2018

ASCO Annual Meeting

Flatiron-authored

Prevalence of Microsatellite Instability and Association with Pembrolizumab (P) Usage in a Real-World Clinico-Genomic Database →

O'Connell C, Backenroth D, Singal G, Agarwala V, Li G, Kaushik G, Alpha-Cobb G, Kao CK, Miller V, Abernethy AP, Carson K

June 2018

ASCO Annual Meeting

Flatiron-authored

Use of Cancer Immunotherapies in the Real-World in the Setting of Microsatellite Instability →

Agarwala V, Gossai A, Singal G, O'Connell C, Li G, Kao K, Bourque D, Feuchtbaum D, Nunnally A, Frampton G, Ali S, Abernethy AP, Kramarz S, Trabucco SE

January 2018

ASCO-SITC Clinical Immuno-Oncology Symposium

Flatiron-authored

An assessment of KRAS, NRAS, and BRAF testing prior to 1st line of therapy among mCRC patients treated at community cancer centers in the United States →

Florea, A, Garawin, T, Sangaré, L, Kelsh, MA, Lowe, K

January 2018

ASCO Gastrointestinal Cancers Symposium

Chemotherapy Use Near End of Life (EOL): Measuring Real World Benchmarks →

Kraut J, Gippetti J, Peterson D, Agarwala V, Revol C, Fessele K, Abernethy AP

March 2017

ASCO Quality Care Symposium

Flatiron-authored

Validation of Diagnosis Codes to Identify Side of Colon in an Electronic Health Record Registry →

Luhn P, Kuk D, Carrigan G, Nussbaum N, Sorg R, Rohrer R, Tucker M, Arnieri B, Taylor M, Abernethy AP

January 2017

ASCO Gastrointestinal Cancers Symposium

Flatiron-authored

The Treatment Continuum of Panitumumab, Cetuximab, and Bevacizumab in 1st Through 3rd Line by KRAS, NRAS, and BRAF Mutation Status Among mCRC Patients Treated at Community Cancer Centers in the United States →

Lowe K, Hool K, Kafatos G, Kelsh M, Garawin T

January 2017

ASCO Gastrointestinal Cancers Symposium

Assessment of Treatment with Panitumumab, Cetuximab, and Bevacizumab Among mCRC Patients with Wild-Type RAS or BRAF Treated and Community Cancer Centers in the United States →

Garawin T, Lowe K, Anthony M, Bohac C

January 2016

ASCO Gastrointestinal Cancers Symposium

Characterization of KRAS, BRAS, and BRAF Testing and Timing Among mCRC Patients Treated At Community Cancer Centers in the United States →

Lowe K, Kelsh M, McCarl M, Bohac C

January 2016

ASCO Gastrointestinal Cancers Symposium